induced pluripotent stem cell therapy derived Novel Gamma Delta Natural Killer T Cell therapy (cytomed therapeutics)

N/A

Report date: 2025/03/20 15:25:30

Base Information

Drug Nameinduced pluripotent stem cell therapy derived Novel Gamma Delta Natural Killer T Cell therapy (cytomed therapeutics)
Drug Alias NameiPSC-gdNKT (Agency For Science Technology & Research)iPSC-gdNKT (CytoMed Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionNatural killer T-lymphocyte stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingaporeMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe Agency for Science Technology and Research
China Registration ClassN/A

Develop Information

Active CompaniesCytomed Therapeutics Pte Ltd
Inactive CompaniesThe Agency for Science Technology and Research
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A